SCHEMBL4877111

SCHEMBL4877111

NC(=O)C(O)c1ccc(O)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 4/20 0.48
TAAR1 Q96RJ0 2/20 0.46
NFKB1 P19838 2/20 0.46
HTR3A P46098 1/20 0.46
TSHR P16473 1/20 0.46
SRC P12931 1/20 0.45
KDM4E B2RXH2 2/20 0.45
ALOX15 P16050 2/20 0.45
APEX1 P27695 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
ESR1 P03372 5/20 0.42
ESR2 Q92731 5/20 0.42
PDCD1 Q15116 1/20 0.42
CD274 Q9NZQ7 1/20 0.42
CA2 P00918 2/20 0.41
CYP3A4 P08684 2/20 0.41
BLM P54132 2/20 0.41
PMP22 Q01453 2/20 0.41
PEPD P12955 1/20 0.41
MPO P05164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22082538 0.81 LMNA (0.39) HIF1ATSHRKDM4EALOX15TDP1
SCHEMBL22081099 0.81 LMNA (0.39) HIF1ATSHRKDM4EALOX15TDP1
SCHEMBL22082536 0.81 LMNA (0.39) HIF1ATSHRKDM4EALOX15TDP1
SCHEMBL5597741 0.80 ESR1 (0.46) HIF1ATAAR1NFKB1HTR3ATSHR
SCHEMBL25309981 0.79 MEN1 (0.49) CA2LMNAMAPK1MEN1CA1
SCHEMBL19716560 0.79 PARP10 (0.46) TSHRTDP1CA2CYP3A4BLM
SCHEMBL19735013 0.79 HDAC3 (0.45) LMNAALDH1A1
SCHEMBL5068688 0.79 BRD4 (0.45) NFKB1TSHRKDM4EALOX15APEX1
SCHEMBL19717863 0.79 BRD4 (0.45) NFKB1TSHRKDM4EALOX15APEX1
SCHEMBL5068690 0.79 BRD4 (0.45) NFKB1TSHRKDM4EALOX15APEX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023237603-A1 RECYCLING METHOD FOR PRODUCING A POLYAMIDE COMPOUND BASF SE (DE) 2023-12-14 WO claimed
US-4407815-A AMINO ACID DERIVATIVE ANTIBIOTICS BEECHAM GROUP LIMITED (GB) 1983-10-04 US claimed
WO-2023237603-A1 RECYCLING METHOD FOR PRODUCING A POLYAMIDE COMPOUND BASF SE (DE) 2023-12-14 WO disclosed
US-20090047699-A1 FLUOROGENIC ENZYME ACTIVITY ASSAY METHODS AND COMPOSITIONS USING FRAGMENTABLE LINKERS APPLIED BIOSYSTEMS INC. (US) 2009-02-19 US disclosed
US-20080038386-A1 Use of a liquid cooling sensate to provide a pungent, warming or tingling sensate composition MOZA ASHOK K 2008-02-14 US disclosed
CN-1136893-C Medicine for curing diabetes 王显勇 2004-02-04 CN disclosed
CN-1326771-A Medicine for curing diabetes WANG XIANYONG (CN) 2001-12-19 CN disclosed
EP-0067518-B1 MODIFIED BETA-LACTAM COMPOUNDS BEECHAM GROUP PLC (GB) 1985-08-21 EP disclosed
US-4517124-A REACTION OF A MERCAPTAN TO FORM ANTIVIOTIC BEECHAM GROUP LIMITED (GB) 1985-05-14 US disclosed
EP-0046363-B1 PROCESS FOR THE PREPARATION OF 2-THIO PENEM DERIVATIVES AND INTERMEDIATES THEREFOR BEECHAM GROUP PLC (GB) 1984-11-14 EP disclosed
EP-0034443-B1 BETA-LACTAM ANTIBACTERIAL COMPOUNDS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM BEECHAM GROUP PLC (GB) 1984-09-26 EP disclosed
US-4463010-A 1-Aza-[3.2.0]-bicycloheptane-2-carboxylic acid, ester or salt thereof BEECHAM GROUP P.L.C. (GB) 1984-07-31 US disclosed
US-4407815-A AMINO ACID DERIVATIVE ANTIBIOTICS BEECHAM GROUP LIMITED (GB) 1983-10-04 US disclosed
US-4387051-A β-Lactam antibiotics, their preparation and their use in pharmaceutical compositions BEECHAM GROUP LIMITED (GB) 1983-06-07 US disclosed
EP-0073100-A1 Beta-lactam compounds, their preparation and their use BEECHAM GROUP PLC (GB) 1983-03-02 EP disclosed
EP-0046363-A1 Process for the preparation of 2-thio penem derivatives and intermediates therefor BEECHAM GROUP PLC (GB) 1982-02-24 EP disclosed
EP-0034443-A2 Beta-lactam antibacterial compounds, their preparation and pharmaceutical compositions containing them BEECHAM GROUP PLC (GB) 1981-08-26 EP disclosed
EP-0028497-A1 Beta-lactam antibiotics, their preparation and their use in pharmaceutical compositions BEECHAM GROUP PLC (GB) 1981-05-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090047699-A1 FLUOROGENIC ENZYME ACTIVITY ASSAY METHODS AND COMPOSITIONS USING FRAGMENTABLE LINKERS BCHE, SI, ENGASE HIF1A 4643/4885TAAR1 3776/4885NFKB1 3651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.